Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis.
Yao-Fan FangJia-Rou LiuShu-Hao ChangChang-Fu KuoLai-Chu SeePublished in: International journal of rheumatic diseases (2022)
Comparable safety issues and mortality rates were observed for JAKis and TNFis in RA patients treated in real-world settings.